昂贵药物目录与多层次保障体系的协同创新&#x02014;&#x02014;新加坡癌症药品支付改革及启示

张欣桐; 吕兰婷

doi:10.19546/j.issn.1674-3830.2025.9.009

中国医疗保险 ›› 2025, Vol. 0 ›› Issue (9) : 78-85. DOI: 10.19546/j.issn.1674-3830.2025.9.009

昂贵药物目录与多层次保障体系的协同创新——新加坡癌症药品支付改革及启示

张欣桐, 吕兰婷

作者信息 +

Collaborative Innovation Between the Expensive Drug Catalog and the Multi-Level Guarantee System——Singapore's Cancer Drug Payment Reform and Its Implications for China

Author information +

文章历史 +

摘要

在癌症药品支出快速增长、医保基金可持续性面临挑战的背景下,新加坡推行了癌症药品支付改革,通过癌症药品目录（Cancer Drug List, CDL）和多层次保障体系的协同创新,实现了成本控制与公平可及的双重目标。本文梳理总结了新加坡癌症药品支付改革的背景、内容及影响,介绍了CDL的基本情况和其准入机制,并探讨了CDL与多层次保障体系在癌症治疗用药支付中的协同作用,最后结合我国多层次保障体系的发展现状提出了相应的政策建议,以期为我国进一步完善高值癌症药品的支付机制提供参考。

Abstract

Under the background of rapid growth in cancer drug expenditure and the challenges to the sustainability of medical insurance funds, Singapore has implemented cancer drug payment reforms. Through collaborative innovation between the Cancer Drug List (CDL) and a multi-level guarantee system, it has achieved the goals of cost control and equitable access. This article reviews and summarizes the background, content, and impact of Singapore's cancer drug payment reforms, introduces the basics of the CDL and its access mechanism, and explores the synergistic effect of the CDL and the multi-level guarantee system in cancer treatment drug payments. Finally, based on the current development of China's multi-level guarantee system, relevant policy recommendations are proposed to provide a reference for further improving the payment mechanism for high-value cancer drugs in China.

导出引用

张欣桐, 吕兰婷. 昂贵药物目录与多层次保障体系的协同创新——新加坡癌症药品支付改革及启示[J]. 中国医疗保险. 2025, 0(9): 78-85 https://doi.org/10.19546/j.issn.1674-3830.2025.9.009

Collaborative Innovation Between the Expensive Drug Catalog and the Multi-Level Guarantee System——Singapore's Cancer Drug Payment Reform and Its Implications for China[J]. China Health Insurance. 2025, 0(9): 78-85 https://doi.org/10.19546/j.issn.1674-3830.2025.9.009

中图分类号： F840.684 C913.7

参考文献

[1] 张欣桐,吕兰婷.新加坡多层次医疗保障体系特点及启示[J].中国医疗保险,2024(11):117-125.
[2] Ministry of Health. MediShield Life Reviews[EB/OL]. (2024-10-26)[2025-05-03]. https://www.moh.gov.sg/managing-expenses/schemes-and-subsidies/medishield-life/medishield-life-review/.
[3] Ministry of Health. Transitional support for cancer patients[EB/OL]. (2022-09-02)[2025-05-04]. https://www.moh.gov.sg/newsroom/transitional-support-for-cancer-patients/.
[4] Ministry of Health. Parliamentary QA-Cancer Drug List[EB/OL]. (2023-02-23)[2025-05-04]. https://www.moh.gov.sg/newsroom/cancer-drug-list/.
[5] Ministry of Health. Cancer Drug List[EB/OL]. (2025-03-31)[2025-05-04]. https://www.moh.gov.sg/newsroom/cancer-drug-list/.
[6] Ministry of Health. FAQs on cancer treatment financing[EB/OL]. (2025-03-19)[2025-05-11]. https://www.moh.gov.sg/managing-expenses/schemes-and-subsidies/medishield-life/faqs-on-cancer-treatment-financing/.
[7] Agency for Care Effectiveness. Methods and process[EB/OL]. (2025-04-22)[2025-05-11]. https://www.ace-hta.gov.sg/resources/process-methods/.
[8] Ministry of Health. Comparison of Integrated Shield Plans[EB/OL]. (2025-02-19)[2025-05-10]. https://www.moh.gov.sg/managing-expenses/schemes-and-subsidies/integrated-shield-plans/comparision-of-integrated-shield-plans/.
[9] PRUDENTIAL. PRUExtra-Health Insurance Singapore[EB/OL]. (2025-05-01)[2025-05-10]. https://www.prudential.com.sg/products/health-insurance/medical/pruextra.